JOUNCE THERAPEUTICS, INC.
780 Memorial Drive
Cambridge, MA 02139
May 17, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Jounce Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-255760
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Jounce Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-255760), so that it may become effective at 4:00 p.m. Eastern time on May 19, 2021, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
Very truly yours,
JOUNCE THERAPEUTICS, INC.
By: /s/ Jacquelyn Fahey Sandell
Name: Jacquelyn Fahey Sandell
Title: Chief Legal Officer and Secretary
cc: Rosemary G. Reilly
Wilmer Cutler Pickering Hale and Dorr LLP
